TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00838227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil
Description: Modafinil up to 400 mg daily will be added to a stable antipsychotic regimen
Study: NCT04123119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine
Description: An exploratory and observational cohort study following infants receiving two standard doses of live, attenuated, oral Rotarix™ administered at 6 \& 10 weeks.
Study: NCT02185131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
Study: NCT01002846

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: acupuncture group : subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth sham acupuncture group : subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture group : subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth sham acupuncture group : subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
Study: NCT00148174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive telephone followup
Description: Telephone calling
Study: NCT02743117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Influenza Vaccine
Description: A single dose of 10\^(7.0 ± 0.5) FFU strain of monovalent influenza vaccine will be administered as intranasal spray on Day 1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo matched to monovalent influenza vaccine will be administered as intranasal spray on Day 1.
Study: NCT04784676

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: restoration
Description: indirect restoration
Study: NCT00582933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF
Description: All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25 mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (thymoglobulin®) prior to transplant to promote engraftment.All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF
Description: All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction.
Study: NCT04784676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: restoration
Description: indirect restoration
Study: NCT02662348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Interleukin-2
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER2Bi-Armed T Cells
Description: Given IV
Study: NCT00582933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF
Description: All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction.
Study: NCT04503564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coil-reinforced soft polymer indwelling cannula
Description: This is a prospective, non-randomized, home-use feasibility study of device performance, usability, tolerability, and safety of the Capillary Biomedical, Inc. (CapBio) Achilles infusion set for continuous subcutaneous insulin infusion (CSII or insulin pump therapy) in up to 20 participants diagnosed with type 1 diabetes mellitus (T1DM).
Study: NCT01077960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serostim
Description: Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment \[Serono Study 24380\] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
Study: NCT03205618

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT00816725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mothers and babies Internet course and PPD informational brochure
Description: An eight-lesson, self-help, Web-based program for the prevention of postpartum depression based on cognitive behavioral therapy, social-learning, and attachment theory. The PPD informational brochure is a four-page pamphlet that contains information about postpartum depression.
Study: NCT03784573

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dog + handler
Description: Dog + handler

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No dog
Description: No dog
Study: NCT00500422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Starting dose of 20 mg/m\^2 IV over 2 hours on Day 1, 21 day cycle
Study: NCT04130204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DYV700
Description: Proprietary transdermal delivery platform

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle transdermal delivery platform

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg
Description: Standard of care, 2 tablets (1.2 mg) loading dose followed by 1 tablet (0.6 mg) 1 hour later at onset of gout flare.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine 0.6 mg
Description: Standard of care, 2 tablets (1.2 mg) loading dose followed by 1 tablet (0.6 mg) 1 hour later at onset of gout flare.
Study: NCT03540602

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tart Cherry
Description: NordicCherry Tart Cherry Extract Powder 500 mg from Specnova, inc
Study: NCT00500422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 500 mg/m\^2 IV over 30 minutes on Days 1 and 8, 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Starting dose of 0.7 mg/m\^2 IV on Days 1 and 8 of first 21 day cycle; increased dose of 1.0 to 1.3 on Days 1, 4, 8, and 11 of subsequent 21 day cycles
Study: NCT00585520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: 200mg BID for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03540602

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule [CEBOCAP]
Description: Rice flour
Study: NCT02315651

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: A snack containing 60 mg of Coenzyme Q10. The snack contains also dried fruits and nuts, and their content are identical to this of placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A snack identical to the trial snack, but without Coenzyme Q10. The snack contains also dried fruits and nuts.
Study: NCT02016638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polysomnography and ambulatory blood pressure recording
Study: NCT00045565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study: NCT03427320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [131]I-IAZA
Description: Injection of a single dose of 185MBq ( range 150-220MBq) of \[131\]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.
Study: NCT00779857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriCure LAA Exclusion System
Description: Exclusion of the left atrial appendage using the AtriCure LAA Exclusion System
Study: NCT03156946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breastfeeding mother-to-mother support
Description: The mother-infant dyads in the intervention arm will receive breastfeeding mother-to-mother support from the hospitalization in the maternity and NICU up to 1 month after discharge. The intervention will be in addition to the usual or routine care. Breastfeeding counselors will be voluntary mothers who breastfed their own preterm infant (aged between 6 months and 5 years at the time of the study) for a minimum of 2 months, and who have had a positive personal breastfeeding experience, and who have undertaken a training course.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: The mother-infant dyads in the control arm will continue to receive the usual/routine care provided by participating centers during the hospitalization and Mother and Infant Protection service after discharge.
Study: NCT03591315

Intervention type: DIAGNOSTIC_TEST
Intervention: resting state fMRI
Description: Define the visual resting state network.

Intervention type: DIAGNOSTIC_TEST
Intervention: resting state fMRI
Description: Define the visual resting state network.

Intervention type: DIAGNOSTIC_TEST
Intervention: visual tasking state fMRI
Description: Using visual task stimulation to identify the activation characteristic of primary visual cortex.

Intervention type: DIAGNOSTIC_TEST
Intervention: visual tasking state fMRI
Description: Using visual task stimulation to identify the activation characteristic of primary visual cortex.

Intervention type: DIAGNOSTIC_TEST
Intervention: diffusion tensor imaging
Description: Define the integrity of white matter fibers in the visual pathway.

Intervention type: DIAGNOSTIC_TEST
Intervention: diffusion tensor imaging
Description: Define the integrity of white matter fibers in the visual pathway.

Intervention type: DIAGNOSTIC_TEST
Intervention: automated visual field
Description: Identify the existence and type of visual field defect.

Intervention type: DIAGNOSTIC_TEST
Intervention: automated visual field
Description: Identify the existence and type of visual field defect.

Intervention type: DIAGNOSTIC_TEST
Intervention: visual acuity
Description: Assess the visual acuity by using ETDRS scales.

Intervention type: DIAGNOSTIC_TEST
Intervention: visual acuity
Description: Assess the visual acuity by using ETDRS scales.
Study: NCT06726499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spherical CRT
Description: Contact lens for myopia progression

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric CRT
Description: Contact lens for myopia progression
Study: NCT01603485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine Immediate-Release (fasted)
Description: Single 500 mg dose of Lersivirine Immediate-Release Tablets (2 x 250 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine Modified-Release #1 (fasted)
Description: Single 500 mg dose of Lersivirine Modified-Release Tablet #1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine Modified-Release #2 (fasted)
Description: Single 500 mg dose of Lersivirine Modified-Release Tablet #2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine Modified-Release #3 (fasted)
Description: Single 500 mg dose of Lersivirine Modified-Release Tablet #3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine Modified-Release (fed)
Description: Single 500 mg dose of Lersivirine Modified-Release Tablet dosed with food.
Study: NCT02471222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADS-5102
Description: Oral capsules to be administered once daily at bedtime for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules to be administered once daily at bedtime for 4 weeks
Study: NCT03731091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%
Description: Once daily for 4 weeks (28 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enstilar® foam (LEO Pharma Inc.)
Description: Once daily for 4 weeks (28 days)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Calcipotriene/ betamethasone dipropionate topical foam
Description: Once daily for 4 weeks (28 days)
Study: NCT03999060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Current Stimulation
Description: Electric stimulation with a Digitimer DS7AH HV Current Stimulator delivered with 4 shielded electrodes mounted on the participants head
Study: NCT01037738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstructive surgery and ACS/ Orthokin application
Description: ACL reconstructive surgery and ACS/ Orthokin or Placebo intraarticular application on Day 0,1,6 and 10 postoperatively, regarding the Arm

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ACL reconstructive surgery and ACS/ Orthokin application
Description: ACL reconstructive surgery and ACS/ Orthokin or Placebo intraarticular application on Day 0,1,6 and 10 postoperatively, regarding the Arm
Study: NCT03089541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey Arm
Description: Contingency Management for completion of surveys and evidence of tobacco use status
Study: NCT02078583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT03521258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dehydrated Human Amnion/Chorion Membrane

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flap-Based Reconstructive Surgery
Description: Standard of Care surgical intervention
Study: NCT00916175

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: P1&P2
Description: * First period (4 weeks) intake food product P1\&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet~* Second period, cross over from AG\&CC group, 4 weeks intake food product P1\&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: P1&CC
Description: * First period (4 weeks) intake food product P1\&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from AG\&P2 group, 4 weeks intake food product P1\&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AG&P2
Description: * First period (4 weeks) intake food product AG\&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from P1\&CC group, 4 weeks intake food product AG\&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AG&CC
Description: * First period (4 weeks) intake food product AG\&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet~* Second period, cross over from P1\&P2 group, 4 weeks intake food product AG\&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TA (concentrated 5:1 aloe vera gel)
Description: * First period (4 weeks) intake food product TA (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from P3 group, 4 weeks intake food product TA (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: P3
Description: * First period (4 weeks) intake food product P3 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from TA group, 4 weeks intake food product P3 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet.
Study: NCT01192971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: apatinib p.o. once daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: apatinib p.o. once daily for 4 weeks
Study: NCT01990677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25mg Eplerenone
Description: Patients will be given 25mg Eplerenone (or 50mg Eplerenone) or placebo throughout the study and the dosage will be based on the serum potassium/creatine levels. Patients will be randomized 2:1 such that 36 patients in each group will receive eplerenone and 16 patients in each group will receive placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25mg Eplerenone
Description: Patients will be given 25mg Eplerenone (or 50mg Eplerenone) or placebo throughout the study and the dosage will be based on the serum potassium/creatine levels. Patients will be randomized 2:1 such that 36 patients in each group will receive eplerenone and 16 patients in each group will receive placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients will be given placebo throughout the study from day one, other patients may be tapered down to placebo based on the serum potassium/creatine levels. 16 patients in each group will receive placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients will be given placebo throughout the study from day one, other patients may be tapered down to placebo based on the serum potassium/creatine levels. 16 patients in each group will receive placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients will be given placebo throughout the study from day one, other patients may be tapered down to placebo based on the serum potassium/creatine levels. 16 patients in each group will receive placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be given placebo throughout the study from day one, other patients may be tapered down to placebo based on the serum potassium/creatine levels. 16 patients in each group will receive placebo.
Study: NCT01874262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile-phone based patient support
Description: The mobile-phone based patient support (investigational medical device) is a stand-alone software product used on the patients' own smart phone and used in addition to medical treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-diary
Description: All patients (active and control group) participating in the study will report their daily use of ticagrelor in an e-diary which will be initiated on all study patients' smart phones.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: e-diary
Description: All patients (active and control group) participating in the study will report their daily use of ticagrelor in an e-diary which will be initiated on all study patients' smart phones.
Study: NCT03588364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulation
Description: Osteopathic manipulation involves a number of different manual techniques. These include muscle inhibition; myofascial release; muscle energy stretch; counterstrain; facilitated positional release ; osteopathy in the cranial field ; balanced ligamentous tension/ligamentous articular strain; one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.